To Top


Company Information

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company committed to the development of first-in-class, effective therapies that harness the power of the tumor microenvironment (TME) to overcome drug resistance and improve treatment outcomes for cancer patients.

Stock Info

Corporate Presentation

Stock Chart

News and Events

EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies
EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies
January 9 2023 at 8:00 am - January 12 at 5:00 pm - UTC+0
November 15 2022 at 8:00 am - November 17 at 5:00 pm - UTC+0
April 8 2022 at 8:00 am - 5:00 pm - UTC+0
August 9 2021 at 8:00 am - August 10 at 5:30 pm - UTC+0
June 4 2021 at 12:00 am - June 8 at 11:59 pm - UTC+0
January 20 2021 at 10:30 am - 11:00 am - UTC+0

Press Releases

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(So...
Purple Biotech Reports First Quarter 2024 Financial Results
CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 - Interim results to be Announced June 1, 2024REHOVOT, Isra...
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purp...
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in respo...
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which in...
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that har...
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.("Purple Biotech" or "the Company") (NASDAQ/TASE:...
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harn...
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business...
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech...
Purple Biotech Reports Third Quarter 2023 Financial Results
Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients' Enrollment in the Phase 2 Randomized CM24 Pancreatic Cancer Trial Ahead of Timelines Cash Runwa...
First | Previous | Next  | Last

SEC Filings

Shareholders' Meetings

Date Files
June 15, 2023 VOTING SLIP FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS Report of Foreign Private Issuer Report of Foreign Private Issuer
August 25, 2022 ea163003-6k_purplebioEDGAR2_Bannerless Instructions-and-Voting-Card-for-2022-GM PURPLE-BIOTECH-LTD-VIF
Dec 22, 2021 Purple-Biotech-Ltd_6-K_Voting-Slip Purple-Biotech-Ltd_6-K_Notice-and-Proxy-Statement 17865-PURPLE-BIOTECH-LTD-KITOV-VIF

Email alerts

Corporate Governance

Purple Biotech Ltd.’s Board of Directors sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Corporate Governance Documents
Code of Ethics Download
Audit Committee Charter Download
Compensation Committee Charter Download
Board Diversity Matrix Download
Audit Committee Compensation Committee
Independent Directors
Dr. Eric Rowinsky
Simcha Rock icon-member-chair-person icon-member
Ido Agmon icon-member icon-member-chair-person
Robert Gagnon icon-member
Suzana Nahum-Zilberberg icon-member
Ori Hershkovitz
Yael Margolin
Non-independent Directors
Isaac Israel
icon-memberMember icon-chair-personChair
Skip to content